Cargando…

How I treat ALK-positive non-small cell lung cancer

Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCusker, Michael G, Russo, Alessandro, Scilla, Katherine A, Mehra, Ranee, Rolfo, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677959/ https://www.ncbi.nlm.nih.gov/pubmed/31423342 http://dx.doi.org/10.1136/esmoopen-2019-000524

Ejemplares similares

Development of autoimmune diabetes with severe diabetic ketoacidosis and immune-related thyroiditis secondary to durvalumab: a case report
por: Lopes, Ana Rita, et al.
Publicado: (2020)

Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date
por: McCusker, Michael G, et al.
Publicado: (2020)

Long-term efficacy of immune checkpoint inhibitors in advanced NSCLC: challenges and opportunities—a commentary of the 3-year follow-up of the KEYNOTE-001 trial
por: Russo, Alessandro, et al.
Publicado: (2019)

Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition
por: Kerner, Gerald S. M. A., et al.
Publicado: (2016)

Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer
por: Barrows, Stephanie M, et al.
Publicado: (2019)

Intracranial and whole-body response of ceritinib in ALK inhibitor-naïve and previously ALK inhibitor-treated patients with ALK-rearranged non-small-cell lung cancer (NSCLC): updated results from the phase 1, multicentre, open-label ASCEND-1 trial
por: Kim, Dong-Wan, et al.
Publicado: (2016)

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung Cancer
por: Isozaki, Hideko, et al.
Publicado: (2015)

Ceritinib for ALK-Rearrangement–Positive Non–Small Cell Lung Cancer
por: Nix, Nancy M., et al.
Publicado: (2015)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

Position‐specific induction of ectopic limbs in non‐regenerating blastemas on axolotl forelimbs
por: McCusker, Catherine, et al.
Publicado: (2014)

Combined effect of ALK and MEK inhibitors in EML4–ALK-positive non-small-cell lung cancer cells
por: Tanizaki, J, et al.
Publicado: (2012)

Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer
por: Shrestha, N., et al.
Publicado: (2019)

Role of STK11 in ALK-positive non-small cell lung cancer
por: Zhou, Wen, et al.
Publicado: (2022)

Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors
por: Chia, Puey Ling, et al.
Publicado: (2014)

The efficacy and safety of ALK inhibitors in the treatment of ALK‐positive non‐small cell lung cancer: A network meta‐analysis
por: Fan, Junsheng, et al.
Publicado: (2018)

Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
por: Waterhouse, David M., et al.
Publicado: (2020)

A Bayesian network meta‐analysis of ALK inhibitor treatments in patients with ALK‐positive non‐small cell lung cancer
por: Zheng, Bei, et al.
Publicado: (2023)

ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer
por: Pilling, Amanda B., et al.
Publicado: (2018)

First-line treatment of advanced ALK-positive non-small-cell lung cancer
por: Gandhi, Shipra, et al.
Publicado: (2015)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Small Cell Lung Cancer: A New Era Is Beginning?
por: Morabito, Alessandro, et al.
Publicado: (2021)

Outcomes of ALK positive lung cancer patients treated with crizotinib or second-generation ALK inhibitor: a monoinstitutional experience
por: De Carlo, Elisa, et al.
Publicado: (2018)

Diagnostic and prognostic biomarkers in oligometastatic non-small cell lung cancer: a literature review
por: Cortinovis, Diego, et al.
Publicado: (2021)

Positional Information Is Reprogrammed in Blastema Cells of the Regenerating Limb of the Axolotl (Ambystoma mexicanum)
por: McCusker, Catherine D., et al.
Publicado: (2013)

Clinical Utility of Circulating Tumor Cells in ALK-Positive Non-Small-Cell Lung Cancer
por: Faugeroux, Vincent, et al.
Publicado: (2014)

Brain Metastasis Mimicking Brain Abscess in ALK-Positive Non-Small-Cell Lung Cancer
por: Sakatani, Toshio, et al.
Publicado: (2019)

ECM-mediated positional cues are able to induce pattern, but not new positional information, during axolotl limb regeneration
por: Vieira, Warren A., et al.
Publicado: (2021)

A pregnant patient with ALK-positive non-small cell lung cancer treated with alectinib: A case report and review of the literature
por: De Smedt, Fabian, et al.
Publicado: (2022)

Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2021)

Understanding positional cues in salamander limb regeneration: implications for optimizing cell-based regenerative therapies
por: McCusker, Catherine D., et al.
Publicado: (2014)

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
por: Marinelli, Daniele, et al.
Publicado: (2022)

Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors
por: Singh, Abhay, et al.
Publicado: (2020)

Addendum: Polyclonal on- and off-target resistance mutations in an EML4-ALK positive non-small cell lung cancer patient under ALK inhibition
por: Kemper, Marcel, et al.
Publicado: (2022)

ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
por: Wang, Michelle, et al.
Publicado: (2023)

The cost-effectiveness of brigatinib in adult patients with ALK inhibitor–naive ALK-positive non–small cell lung cancer from a US perspective
por: Cranmer, Holly, et al.
Publicado: (2022)

Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide
por: Park, Sook-Eun, et al.
Publicado: (2011)

A Systematic Review of Companion Diagnostic Tests by Immunohistochemistry for the Screening of Alectinib-Treated Patients in ALK-Positive Non-Small Cell Lung Cancer
por: Kang, Sulim, et al.
Publicado: (2022)

Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer
por: Nishio, Makoto, et al.
Publicado: (2018)

Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer
por: Kang, Jin, et al.
Publicado: (2018)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1kug5o0ouosblabt5nbu000d4k